Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Actinic (Solar) Keratosis Treatment Pipeline Review H2 2016

Monday, October 17, 2016 3:38
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Actinic (Solar) Keratosis – Pipeline Review, H2 2016’, provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685896-actinic-solar-keratosis-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis 
- The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects 
- The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @https://www.wiseguyreports.com/reports/685896-actinic-solar-keratosis-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Actinic (Solar) Keratosis Overview 9 
Therapeutics Development 10 
Pipeline Products for Actinic (Solar) Keratosis – Overview 10 
Pipeline Products for Actinic (Solar) Keratosis – Comparative Analysis 11 
Actinic (Solar) Keratosis – Therapeutics under Development by Companies 12 
Actinic (Solar) Keratosis – Therapeutics under Investigation by Universities/Institutes 13 
Actinic (Solar) Keratosis – Pipeline Products Glance 14 
Late Stage Products 14 
Clinical Stage Products 15 
Early Stage Products 16 
Unknown Stage Products 17 
Actinic (Solar) Keratosis – Products under Development by Companies 18 
Actinic (Solar) Keratosis – Products under Investigation by Universities/Institutes 19 
Actinic (Solar) Keratosis – Companies Involved in Therapeutics Development 20 
3M Drug Delivery Systems 20 
Athenex, Inc. 21 
Digna Biotech, S.L. 22 
Foamix Pharmaceuticals Ltd. 23 
G&E Herbal Biotechnology Co., Ltd. 24 
Galderma S.A. 25 
Laboratories Ojer Pharma S.L. 26 
LEO Pharma A/S 27 
Novartis AG 28 
Oncology Research International Limited 29 
Promius Pharma, LLC 30 
Spherium Biomed S.L. 31 
Valeant Pharmaceuticals International, Inc. 32 
Vectura Group Plc 33 
Actinic (Solar) Keratosis – Therapeutics Assessment 34 
Assessment by Monotherapy Products 34 
Assessment by Combination Products 35 
Assessment by Target 36 
Assessment by Mechanism of Action 38 
Assessment by Route of Administration 40 
Assessment by Molecule Type 42 
Drug Profiles 44 
854-A – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
ACT-01 – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
AD-17137 – Drug Profile 46 
Product Description 46 
Mechanism Of Action 46 
R&D Progress 46 
celecoxib – Drug Profile 47 
Product Description 47 
Mechanism Of Action 47 
R&D Progress 47 
DFD-08 – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
disitertide – Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
hydrogen peroxide + sulindac – Drug Profile 51 
Product Description 51 
Mechanism Of Action 51 
R&D Progress 51 
IDP-125 – Drug Profile 52 
Product Description 52 
Mechanism Of Action 52 
R&D Progress 52 
IDP-128 – Drug Profile 53 
Product Description 53 
Mechanism Of Action 53 
R&D Progress 53 
imiquimod – Drug Profile 54 
Product Description 54 
Mechanism Of Action 54 
R&D Progress 54 
imiquimod SR – Drug Profile 55 
Product Description 55 
Mechanism Of Action 55 
R&D Progress 55 
KX-01 – Drug Profile 56 
Product Description 56 
Mechanism Of Action 56 
R&D Progress 56 
LEO-43204 – Drug Profile 58 
Product Description 58 
Mechanism Of Action 58 
R&D Progress 58 
LFX-453 – Drug Profile 59 
Product Description 59 
Mechanism Of Action 59 
R&D Progress 59 
ORIL-007 – Drug Profile 60 
Product Description 60 
Mechanism Of Action 60 
R&D Progress 60 
Recombinant Peptide for Dermatology, Immunology and Oncology – Drug Profile 61 
Product Description 61 
Mechanism Of Action 61 
R&D Progress 61 
resiquimod – Drug Profile 62 
Product Description 62 
Mechanism Of Action 62 
R&D Progress 62 
SKP-024 – Drug Profile 63 
Product Description 63 
Mechanism Of Action 63 
R&D Progress 63 
Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer – Drug Profile 64 
Product Description 64 
Mechanism Of Action 64 
R&D Progress 64 
SP-12054 – Drug Profile 65 
Product Description 65 
Mechanism Of Action 65 
R&D Progress 65 
SRT-100 – Drug Profile 66 
Product Description 66 
Mechanism Of Action 66 
R&D Progress 66 
VDA-1102 – Drug Profile 68 
Product Description 68 
Mechanism Of Action 68 
R&D Progress 68 
VPE-001 – Drug Profile 69 
Product Description 69 
Mechanism Of Action 69 
R&D Progress 69 
Actinic (Solar) Keratosis – Dormant Projects 70 
Actinic (Solar) Keratosis – Discontinued Products 72 
Actinic (Solar) Keratosis – Product Development Milestones 73 
Featured News & Press Releases 73 
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 73 
Appendix 74 
Methodology 74 
Coverage 74 
Secondary Research 74 
Primary Research 74 
Expert Panel Validation 74 
Contact Us 74 
Disclaimer 75

List of Tables 
Number of Products under Development for Actinic (Solar) Keratosis, H2 2016 10 
Number of Products under Development for Actinic (Solar) Keratosis – Comparative Analysis, H2 2016 11 
Number of Products under Development by Companies, H2 2016 12 
Number of Products under Investigation by Universities/Institutes, H2 2016 13 
Comparative Analysis by Late Stage Development, H2 2016 14 
Comparative Analysis by Clinical Stage Development, H2 2016 15 
Comparative Analysis by Early Stage Development, H2 2016 16 
Comparative Analysis by Unknown Stage Development, H2 2016 17 
Products under Development by Companies, H2 2016 18 
Products under Investigation by Universities/Institutes, H2 2016 19 
Actinic (Solar) Keratosis – Pipeline by 3M Drug Delivery Systems, H2 2016 20 
Actinic (Solar) Keratosis – Pipeline by Athenex, Inc., H2 2016 21 
Actinic (Solar) Keratosis – Pipeline by Digna Biotech, S.L., H2 2016 22 
Actinic (Solar) Keratosis – Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 23 
Actinic (Solar) Keratosis – Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 24 
Actinic (Solar) Keratosis – Pipeline by Galderma S.A., H2 2016 25 
Actinic (Solar) Keratosis – Pipeline by Laboratories Ojer Pharma S.L., H2 2016 26 
Actinic (Solar) Keratosis – Pipeline by LEO Pharma A/S, H2 2016 27 
Actinic (Solar) Keratosis – Pipeline by Novartis AG, H2 2016 28 
Actinic (Solar) Keratosis – Pipeline by Oncology Research International Limited, H2 2016 29 
Actinic (Solar) Keratosis – Pipeline by Promius Pharma, LLC, H2 2016 30 
Actinic (Solar) Keratosis – Pipeline by Spherium Biomed S.L., H2 2016 31 
Actinic (Solar) Keratosis – Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 32 
Actinic (Solar) Keratosis – Pipeline by Vectura Group Plc, H2 2016 33 
Assessment by Monotherapy Products, H2 2016 34 
Assessment by Combination Products, H2 2016 35 
Number of Products by Stage and Target, H2 2016 37 
Number of Products by Stage and Mechanism of Action, H2 2016 39 
Number of Products by Stage and Route of Administration, H2 2016 41 
Number of Products by Stage and Molecule Type, H2 2016 43 
Actinic (Solar) Keratosis – Dormant Projects, H2 2016 70 
Actinic (Solar) Keratosis – Dormant Projects (Contd..1), H2 2016 71 
Actinic (Solar) Keratosis – Discontinued Products, H2 2016 72

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685896

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.